Skip to main content

Instil Bio, Inc.

TIL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001789769

No open-market purchases or sales by Instil Bio, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $29.2M in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Instil Bio, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of TIL: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders7362−11
Shares92.1M82.1M−9.98M (−10.8%)
Value$60.9M$45.3M−$15.6M (−25.7%)

New holders (13)

Institutions that held Instil Bio, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to TIL in Q2 2023
InstitutionSharesValue% of portfolio
Jacobs Levy Equity Management, Inc213,734$117.8K0.00%
Gsa Capital Partners LLP204,811$113.0K0.01%
Y-Intercept (Hong Kong) Ltd161,486$89.0K0.01%
Qube Research & Technologies Ltd104,281$57.5K0.00%
Bridgeway Capital Management, LLC59,500$32.8K0.00%
Cubist Systematic Strategies, LLC21,616$11.9K0.00%
Balyasny Asset Management LLC16,463$9.07K0.00%
Old Mission Capital LLC15,838$8.73K0.00%
Commerce Bank13,463$7.42K0.00%
Fidelis Capital Partners, LLC13,268$7.31K0.00%
Point72 Middle East FZE10,636$5.86K0.00%
Point72 Asset Management, L.P.5,247$2.89K0.00%
Nisa Investment Advisors, LLC100$550.00%

Sold out (24)

Institutions that held Instil Bio, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.